NP

Neptune is a genuinely high-quality business. As an MGA it takes no balance-sheet insurance risk and handles no claims — capacity providers do — so it runs a capital-light, recurring, fee-based model: revenue compounded $84.9M → $119M → $160M (+33.7% in FY2025), operating margin is 44.5%, net margin 23.4%, and it threw off $51.7M of operating cash flow with zero long-term or current debt. The model's durability shows in the disclosures: 91.7% of FY2024 policy revenue renewed into FY2025, premium retention at renewal was 98% and policy retention 86%, all driven by the proprietary Triton AI underwriting engine and a diversified panel of 40 capacity providers (32 reinsurers) backing 8 programs. This is a structurally attractive, asset-light compounder.

The problem is what you pay and what the headline numbers hide. At $30.48 the stock trades at ~20x trailing sales and roughly ~85x GAAP net income — a price that already discounts years of flawless execution from a company that only IPO'd on October 2, 2025 and thus has a very thin public track record. And while revenue grew 33.7%, operating income rose just 3.7% and net income only 8.2%: the gap is $11.4M of share-based compensation (up from $0.3M) and $8.9M of IPO transaction costs. The IPO costs are one-time and were largely reimbursed by selling stockholders, but the SBC is a recurring, real dilution — shares already grew 11.9%. Most jarring, diluted EPS is -$0.26 despite $37.4M of net income, a function of the post-IPO capital structure / preferred mechanics, and the balance sheet carries -$227M stockholders' equity on -$514M of accumulated deficit, a legacy of pre-IPO recapitalization rather than operating distress (debt is now zero and cash flow is strongly positive).